View Older Stories
-
AstraZeneca (AZN) call put ratio 1.7 calls to 1 put into share price lower before the bell
-
Bernstein says risk-reward is positively skewed for this pharma stock
-
EU approves AstraZeneca and Daiichi Sankyo's Datroway for breast cancer
-
AstraZeneca says adjusting drug pricing over Trump policies
-
AstraZeneca drug shows survival benefit in gastric cancer trial
-
AstraZeneca (AZN) Tops Q2 EPS by 14c
-
AstraZeneca's Ultomiris misses primary endpoint in adult HSCT-TMA trial
-
AstraZeneca drug shows survival benefit in gastric cancer trial
-
AstraZeneca (AZN) Q2 earnings preview
-
Enhertu combination gets EU approval recommendation for breast cancer
-
AstraZeneca's Trixeo receives EU recommendation for asthma treatment
-
Alnylam Pharmaceuticals (ALNY) PT Raised to $485 at H.C. Wainwright
-
AstraZeneca licenses sunvozertinib from Dizal for $600M upfront
-
AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
-
BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright
-
HSBC Downgrades AstraZeneca (AZN:LN) (AZN) to Hold
-
Bernstein keeps telling clients to buy this pharma stock
-
Buy the pullback in this major pharma stock: Bernstein
-
AstraZeneca (AZN) call put ratio 1.9 calls to 1 put with a focus on July 180 and 190 calls
-
AstraZeneca's Wainua fails primary endpoint in heart trial
-
Abbisko and AstraZeneca to trial oral PD-L1 drug with Tagrisso
-
AstraZeneca's Datroway recommended for EU approval in breast cancer
-
AstraZeneca and YMCA of the USA form five-year cancer care deal
-
AstraZeneca unit receives FDA priority review for rare kidney disease treatment
-
AstraZeneca receives FDA approval for Truqap prostate cancer treatment
-
BofA Securities Reiterates Buy Rating on AstraZeneca (AZN:LN) (AZN)
-
AstraZeneca's Ultomiris shows 46.6% reduction in kidney protein levels
-
Ultomiris shows 43% reduction in kidney protein levels in rare disease trial
-
AstraZeneca reports positive SERENA-6 trial results for camizestrant
-
AstraZeneca IMFINZI combo cuts liver cancer progression risk by 30%
-
FDA Approves Durvalumab in Combination with Bacillus Calmette-Guerin for High-Risk Non-Muscle Invasive Bladder Cancer
-
FDA extends review period for AstraZeneca breast cancer drug camizestrant
-
DATROWAY approved in US for first-line metastatic triple-negative breast cancer
-
Daiichi Sankyo gets US approval for Datroway in metastatic breast cancer
-
AstraZeneca's camizestrant wins EU panel backing for breast cancer
-
Trump to unveil more discounted prescription drug options - CNBC
-
AstraZeneca's BAXFENDY wins FDA approval for resistant hypertension
-
AstraZeneca receives FDA approval for hypertension drug Baxfendy
-
AstraZeneca drug combo shows survival benefit in bladder cancer trial
-
AstraZeneca drug meets primary endpoint in rare disease trial
-
Health officials explore restrictions on certain SSRI antidepressants - Reuters
-
FDA Advisory Committee recommends TRUQAP for prostate cancer subtype
-
FDA Panel Votes 6-3 'no' On Astrazeneca Breast Cancer Drug
-
AstraZeneca (AZN) Tops Q1 EPS by 6c; offers guidance
-
AstraZeneca Q1 preview: In-line quarter expected as pipeline catalysts take center stage
-
AstraZeneca, Amgen partner with FDA to test real-time AI trial monitoring
-
AstraZeneca's BREZTRI wins US approval for asthma treatment
-
AstraZeneca wins FDA approval for SAPHNELO autoinjector pen for lupus
-
AstraZeneca's tozorakimab meets primary endpoint in Phase III COPD trial
-
AstraZeneca reports positive Phase III trial results for COPD drug
